【摘要】：研究目的 研究冠心病中成藥的配伍規(guī)律。 研究方法 檢索中華人民共和國(guó)國(guó)家知識(shí)產(chǎn)權(quán)局2004-2014年冠心病中成藥專利,采用雙人雙機(jī)獨(dú)立錄入Microsoft Excle2010表格,將相異率控制在3%以下,主要采用頻數(shù)計(jì)數(shù)法進(jìn)行統(tǒng)計(jì)分析。 結(jié)果 冠心病中成藥最常用的單味中藥為丹參(53.88%)、川芎(38.60%)、三七(34.84%)、黃芪(30.82%)、紅花(25.31%)、當(dāng)歸(23.81%)；最常用的藥對(duì)為丹參-川芎(27.07%)、丹參-黃芪(21.80%)、丹參-三七(21.55%)、丹參-紅花(17.54%)、川芎-黃芪(17.29%)；最常用的角藥為丹參-川芎-黃芪(12.78%)、丹參-川穹-紅花(12.28%)、丹參-川芎-三七(11.28%)、丹參-川芎-當(dāng)歸(11.28%)、川芎-黃芪-當(dāng)歸(9.77%)。 結(jié)論 冠心病中成藥配伍有規(guī)律可循。提示今后研發(fā)冠心病中成藥應(yīng)優(yōu)先選用活血、補(bǔ)氣、補(bǔ)血類中藥；單味藥優(yōu)先選用丹參、川芎、三七等；藥對(duì)優(yōu)先選用丹參-川芎、丹參-黃芪等；角藥優(yōu)先選用丹參-川芎-黃芪、丹參-川穹-紅花等,進(jìn)而為研發(fā)新的高效的中成藥提供了一定的依據(jù)。
[Abstract]:Objective to study the compatibility of proprietary Chinese medicine for coronary heart disease (CAD). Methods the patent of proprietary Chinese medicine for coronary heart disease was searched by the State intellectual property Office of the people's Republic of China from 2004 to 2014. The Microsoft Excle2010 table was input independently by double computers, and the difference rate was controlled below 3%. The frequency counting method was mainly used for statistical analysis. Results the most commonly used traditional Chinese medicine for coronary heart disease were Salvia miltiorrhiza (53.88%), Ligusticum chuanxiong (38.60%), Panax notoginseng (34.84%), Astragalus membranaceus (30.82%), safflower (25.31%) and Angelica sinensis (23.81%). The most commonly used drugs were Radix Salviae Miltiorrhiza-Ligusticum chuanxiong (27.07%), Radix Salviae Miltiorrhiza-Astragalus (21.80%), Salvia miltiorrhiza-Panax notoginseng (21.55%), Salvia miltiorrhiza-safflower (17.54%) and Ligusticum chuanxiong-Astragalus membranaceus (17.29%). The most commonly used horn drugs were Salvia miltiorrhiza-Ligusticum chuanxiong-Astragalus membranaceus (12.78%), Salvia miltiorrhiza-Chuanqiong-safflower (12.28%), Salvia miltiorrhiza-Ligusticum chuanxiong-Panax notoginseng (11.28%), Radix Rhizoma Chuanxiong-Angelica (11.28%) and Ligusticum chuanxiong-Astragalus membranaceus-Angelica sinensis (9.77%). Conclusion the compatibility of proprietary Chinese medicine in coronary heart disease can be followed regularly. It is suggested that in the future, priority should be given to activating blood circulation, invigorating qi and replenishing blood circulation, giving priority to salvia miltiorrhiza, Ligusticum chuanxiong, Panax notoginseng, etc.; giving priority to salvia miltiorrhiza, Ligusticum chuanxiong, Radix Astragali, etc.; giving priority to Radix Salviae Miltiorrhiza, Ligusticum chuanxiong, Salvia miltiorrhiza and safflower, etc., which provides a certain basis for the research and development of new and efficient proprietary Chinese medicines.
【學(xué)位授予單位】：北京中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R289.1

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 蘇雁濤;;謅議三七[J];當(dāng)代醫(yī)學(xué);2009年13期

2 何耀,李良?jí)?萬(wàn)志恒,李蘭蓀,鄭笑蓮,賈國(guó)良;冠心病危險(xiǎn)因素的病例對(duì)照研究[J];解放軍預(yù)防醫(yī)學(xué)雜志;1992年06期

3 王振濤;韓麗華;朱明軍;張淑娟;曹生海;;川芎嗪注射液促心梗后大鼠缺血心肌血管新生作用及對(duì)相關(guān)生長(zhǎng)因子影響的研究[J];遼寧中醫(yī)雜志;2006年07期

4 王南，蔡海江，朱宇，陳秀英;丹參素對(duì)牛主動(dòng)脈平滑肌細(xì)胞氧化修飾LDL的抑制作用[J];南京醫(yī)科大學(xué)學(xué)報(bào);1994年04期

5 陳文塏，難波恒雄，，鳥(niǎo)取冢和生;三種東川芎提取物的抗血小板聚集作用[J];南京中醫(yī)藥大學(xué)學(xué)報(bào);1995年04期

6 張曉星;龔恬;張立平;;冠心病從腎論治[J];新中醫(yī);2008年05期

7 楊玉霞,吳衛(wèi),鄭有良;紅花研究進(jìn)展[J];四川農(nóng)業(yè)大學(xué)學(xué)報(bào);2004年04期

8 張京春;謝元華;;陳可冀院士辨治冠心病醫(yī)案的數(shù)據(jù)挖掘[J];世界中西醫(yī)結(jié)合雜志;2008年01期

9 任耀龍;王永剛;鄭剛;;補(bǔ)腎法治療中老年冠心病機(jī)理探析[J];山西中醫(yī);2013年07期

10 王鵬;冠心病心絞痛辨證論治研究的現(xiàn)狀及分析[J];中國(guó)中醫(yī)藥信息雜志;1997年05期

本文編號(hào)：2507890